UCB SA - Company Profile
Powered by 
All the sales intelligence you need on UCB SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how UCB SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with UCB SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View more- Top 10 Pharmaceutical Companies in Europe in 2022 by Market Capitalization
- Top 10 Pharma Companies in Europe in 2021 by R&D Expenditure
- Top 10 Big Biopharma Companies (Large Pharma & Large Biotech) in Europe in 2021 by Revenues
- Top 10 Pharmaceutical Companies in the World in 2022 by Market Capitalization
Business Description
UCB SA (UCB) develops, manufactures, sells and distributes pharmaceuticals for the treatment of people living with severe neurological and immunological disorders. The company’s products portfolio includes five core medicines BIMZELX, RYSTIGGO, ZILBRYSQ, FINTEPLA and EVENITY.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
UCB's R&D arm focuses on innovation in the discovery, development, and delivery of medicines. The company fosters a culture of innovation by providing the right surroundings and facilities, hiring talented individuals, and seeking new knowledge and skills. UCB is committed to building a dynamic environment for creative minds to push the boundaries of what is possible in R&D. The company also hosts a science podcast, "Hypothesize That!," which explores provocative trends and theories shaping the future of Pharma R&D. The R&D units of UCB include strategic research centers, research satellites, manufacturing sites, and development sites. These units are responsible for managing the company's R&D activities, including discovery, research, development, and manufacturing. UCB has 3 strategic research centers, 3 research satellites, 4 manufacturing sites, and 7 development sites. The company employs over 1,700 researchers across 6 countries. UCB has a strong pipeline spanning several therapy areas, with multiple products in various phases of development. The company is involved in technology alliances, such as its partnership with Stanford University for digital phenotyping and computational discovery, and with the University of California San Francisco for building a comprehensive HS patient registry. In FY2025, the company spent EUR1,822 million on its R&D activities, which as a percentage of revenue stood at 23.5% and grew 2.3% YoY.
Product Categories
Overview
Includes Zyrtec (cetirizine, including Zyrtec-D/Cirrus), Xyzal (levocetirizine) and other products. -Xyzal and Zyrtec are indicated for the treatment of allergic rhinitis, including persistent allergic rhinitis and urticaria.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes Cimzia (certolizumab pegol) and Evenity (romosozumab). - Cimzia is tumor necrosis factor (TNF) blocker approved for the treatment of Crohn’s disease; rheumatoid arthritis; psoriatic arthritis; axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis and ankylosing spondylitis. UCB markets and distributes Cimzia in partnership with Astellas in Japan. - Evenity (romosozumab), a bone forming monoclonal antibody for the treatment of osteoporosis. It is co-developed and co-commercialized by UCB and Amgen. -Bimzelx approved for the treatment of moderate to severe plaque psoriasis in adults.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Core product portfolio consists of Vimpat (lacosamide), Keppra (levetiracetam), Briviact (brivaracetam), Nayzilam (midazolam) and Neupro (rotigotine). - Vimpat is approved in the US as an adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 4 years of aged and older and is approved in Europe as monotherapy and adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy. Vimpat is available as film-coated tablets, syrup and solution for infusion. - Keppra is approved for the treatment of partial-onset seizures, epilepsy primary generalized tonic-clonic (PGTCS) with idiopathic generalized epilepsy and for myoclonic seizures with juvenile myoclonic epilepsy. - Briviact (brivaracetam) is indicated as adjunctive therapy for the treatment of partial-onset seizures. - Neupro (rotigotine) is approved for Parkinson’s disease and restless legs syndrome. - Nayzilam (midazolam), a nasal spray approved in the US for the treatment of acute, intermittent, and stereotypic episodes of seizure clusters, acute repetitive seizures in patients with epilepsy. - The company markets Keppra and Neurpro in partnership with Otsuka and Vimpat in partnership with Daiichi Sankyo in Japan.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Target Markets
Includes Austria, Germany, Spain, France (including French territories), Belgium, Sweden, Italy, the UK and Ireland.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Target Markets
Includes Australia, Turkey, Canada, Brazil, Hong Kong, Taiwan, India, Mexico, Russia, South Korea, China, and Ukraine.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer